Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine in children with sickle cell disease
NCT05084521Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of famotidine in sickle cell disease (SCD), sponsored by Assistance publique - Hôpitaux de Paris. Started Jan 2022; status: completed.
02
Drugs
famotidine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05084521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05084521.